Romano Danesi has been Professor of Pharmacology at the University of Pisa, Italy, since 2005. He received his MD degree in 1983 from the University of Pisa. He obtained a PhD degree in Pharmacology from the Superior School S. Anna, Pisa (Italy) and board certifications in Respiratory Diseases and Tisiology (1988), Clinical Pharmacology (2001) and Clinical Oncology (2006) from the University of Pisa, Italy. He was Assistant Professor of Pharmacology from 1991 to 1998 at the Superior School S. Anna (Pisa), and then Associate Professor of Chemotherapy from 1998 to 2005.
Professor Danesi was awarded fellowships of the Italian Association for Cancer Research (AIRC), the Italian Foundation of Cancer Research (FIRC), and the European Organization for Research and Treatment of Cancer (EORTC). He also received a fellowship from the US Public Health Service (USPHS) to work as a visiting fellow in the Medicine Branch/Clinical Pharmacology Branch, NCI, NIH, Bethesda, MD (USA), from 1998 to 1990 and as Assistant Professor of Hematology/Oncology in the Division of Hematology-Oncology of the University of Virginia at Charlottesville (USA) from 1993 to 1994.
Dr Danesi’s main research fields, in chronological order, are the mechanisms of cardiotoxicity anthracyclines, the characterisation of angiogenic activity of members of FGF family and of antiangiogenic drugs against FGF and PDGF, the mechanisms of ras isoprenylation and activity of novel inhibitors of protein geranylgeranylation, and, finally, the pharmacogenetics of anticancer agents in order to identify the relationships between genotype and response to treatment and toxicity, in particular between the genotype of metabolic enzymes and transporters of nucleoside analogues and steroid hormones and survival of patients with pancreas and prostate cancers. More recently, his research activities have focused on the molecular analysis of circulating nucleic acids as a tool to investigate the mechanisms of resistance to targeted agents in lung, prostate and breast cancers.
He has published 390 full papers in international journals of oncology and pharmacology and, since 2002, he has been a reviewer of research projects within the 6th, 7th and H2020 Framework Programmes of the European Commission.
EM-06830 - Date of preparation: March 2019